Exelixis Inc. Common Stock vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Exelixis Inc. Common Stock trades at $60.73 (market cap $14.62B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.29 (market cap $28.50B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is the larger of the two by market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| EXEL | LQD | |
|---|---|---|
Market Cap | $14.62B | $28.50B |
Volume | 2,684,957 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $59.13 | $112.91 |
52-Week Low | $34.54 | $101.83 |
Typical Hold Time | 0 Days | 125 Days |
Enterprise Value | $13.95B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $102.295, up slightly by 0.17% on the day. The technical outlook is bearish, with moving averages signaling selling pressure, while oscillators are neutral. Recent news highlights a significant increase in short interest and a challenging environment for bonds due to rising yields. The fund maintains a 4.8% yield, with recent dividend payments, but faces headwinds from higher interest rates impacting corporate borrowing costs.
The outlook for LQD is cautious amid a rising rate environment, which pressures bond prices. Investment opportunities lie in its high-quality corporate bond portfolio and steady yield, but risks include further yield increases and economic slowdowns affecting credit quality. Investors should weigh the fund's income generation against interest rate sensitivity and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →